2018
DOI: 10.1186/s13000-018-0692-1
|View full text |Cite
|
Sign up to set email alerts
|

Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing

Abstract: Background: Plasma cell myeloma (PCM) is a neoplasm of terminally differentiated B lymphocytes with molecular heterogeneity. Although therapy-related myeloid neoplasms are common in plasma cell myeloma patients after chemotherapy, transdifferentiation of plasma cell myeloma into myeloid neoplasms has not been reported in literature. Here we report a very rare case of myeloid neoplasm transformed from plasma cell myeloma. Case presentation: A 60-year-old man with a history of plasma cell myeloma with IGH-MAF ge… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 48 publications
0
1
0
Order By: Relevance
“…Another suggested mechanism is that the MM will lead to the activation of numerous gene expression profiles and molecular pathways leading to the formation of myeloid neoplasm. A recently published case report described the transdifferentiation of myeloid sarcoma from PCM, where next-generation sequencing demonstrated a clonal relationship between the PCM and transferred tumor cells, including loss of tumor suppressor gene, and multiple clonal mutations in the RAS pathway [ 8 , 9 ].…”
Section: Discussionmentioning
confidence: 99%
“…Another suggested mechanism is that the MM will lead to the activation of numerous gene expression profiles and molecular pathways leading to the formation of myeloid neoplasm. A recently published case report described the transdifferentiation of myeloid sarcoma from PCM, where next-generation sequencing demonstrated a clonal relationship between the PCM and transferred tumor cells, including loss of tumor suppressor gene, and multiple clonal mutations in the RAS pathway [ 8 , 9 ].…”
Section: Discussionmentioning
confidence: 99%